β-Lactam/β-Lactamase Inhibitor Combinations: From Then to Now

Annals of Pharmacotherapy

Volumn 49, Issue 1, 2015, Pages 86-98

  Toussaint, Kimberly A ^a   Gallagher, Jason C ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

avibactam; bacterial resistance; carbapenemase; clavulanate; MK 7655; relebactam; RPX7009; sulbactam; tazobactam; lactamase; lactamase inhibitor

Indexed keywords

7 OXO N (4 PIPERIDINYL) 1,6 DIAZABICYCLO[3.2.1]OCTANE 2 CARBOXAMIDE; AMOXICILLIN; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEMASE; CEFTAROLINE; CEFTOLOZANE PLUS TAZOBACTAM; CLAVULANIC ACID; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; RELEBACTAM; RPX 7009; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIA; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG IDENTIFICATION; IN VITRO STUDY; INFECTION; INFECTION CONTROL; INTRINSIC ACTIVITY; MEDLINE; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIPELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG COMBINATION; HUMAN; METABOLISM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84919629764     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014556652     Document Type: Review

References (112)

1. Wilke M,Lovering A,Strynadka N.Beta-lactam antibiotic resistance: a current structural perspective.Curr Opin Microbiol. 2005;8:525-533
2. Gupta N,Limbag B,Patel J,Kallen A.Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.Clin Infect Dis. 2011;53:60-67
3. Schwaber MJ,Klarfeld-Lidji S,Navon-Venezia S,Schwartz D,Leavitt A,Carmeli Y.Predictors of carbapenem-resistant Klebsiella pneumonia acquisition among hospitalized adults and effect of acquisition on mortality.Antimicrob Agents Chemother. 2008;52:1028-1033
4. Tumbarello M,Viale P,Viscoli C, et al.Predictors of mortality in bloodstream infections caused by Klebsiella pneumonia carbapenemase-producing K. pneumoniae: importance of combination therapy.Clin Infect Dis. 2012;55:943-950
5. Livermore DM.Beta-lactamases in laboratory and clinical resistance.Clin Microbiol Rev. 1995;8:557-584
6. Livermore DM.Determinants of the activity of beta-lactamase inhibitor combinations.J Antimicrob Chemother. 1993;31:9-21
7. Bush K.Beta-lactamase inhibitors from laboratory to clinic.Clin Microbiol Rev. 1988;1:109-123
8. Medeiros A.Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.Clin Infect Dis. 1997;24:S19-S45
9. Sirot D.Extended-spectrum plasmid-mediated beta lactamases.J Antimicrob Chemother. 1995;36:19-34
10. Jacoby G,Munoz-Price LS.The new beta-lactamases.N Engl J Med. 2005;352:380-391
11. Lister P.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000;20:213S-218S
12. Livermore DM.Clinical significance of beta-lactamase induction and stable depression in Gram-negative rods.Eur J Clin Microbiol. 1987;6:439-445
13. Paterson D.Resistance in Gram negative bacteria: Enterobacteriaceae.Am J Med. 2006;119:S20-S28
14. Leonard D,Bonomo K,Powers R.Class D beta-lactamases: a reappraisal after five decades.Acc Chem Res. 2013;46:2407-2415
15. Bush K,Jacoby GA,Medeiros A.A functional classification scheme for beta-lactamases and its correlation with molecular structure.Antimicrob Agents Chemother. 1995;39:1211-1233
16. Bush K,Jacoby GA.Updated functional classification of beta-lactamases.Antimicrob Agents Chemother. 2010;54:969-976
17. Bush K.New beta-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.Clin Infect Dis. 2001;32:1085-1089
18. Lacey R,Kruczenk S.Epidemiology of antibiotic resistance in Staphylococcus aureus.J Antimicrob Chemother. 1986;18:207-214
19. Livermore D.Beta-lactamase mediated resistance and opportunities for its control.J Antimicrob Chemother. 1998;41:25-41
20. Queenan AM,Bush K.Carbapenemases: the versatile beta-lactamases.Clin Microbiol Rev. 2007;20:440-458
21. Tamilselvi A,Mugesh G.Zn and antibiotic resistance: metallo beta-lactamases and their synthetic analogues.J Biol Inorg Chem. 2008;13:1039-1053
22. Aoki N,Ishii Y,Tateda K, et al.Efficacy of calcium-EDTA as an inhibitor for metallo beta-lactamases in a mouse model of Pseudomonas aeruginosa pneumonia.Antimicrob Agents Chemother. 2010;54:4582-4588
23. Jacoby G.AmpC beta-lactamases.Clin Microbiol Rev. 2009;22:161
24. Jones R.Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the AmpC enzymes.Diagn Microbiol Infect Dis. 1998;31:461-466
25. Ledent P,Raquet K,Joris B, et al.A comparative study of class D beta-lactamases.Biochem J. 1993;292:555-562
26. Poirel L,Naas T,Nordmann P.Diversity, epidemiology, and genetics of class D beta-lactamases.Antimicrob Agents Chemother. 2010;54:24-38
27. Naas T,Sougakoff W,Casetta A, et al.Molecular characterization of OXA-20, a novel, Class D beta-lactamase, and its integrin from Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1998;42:2074-2083
28. Brown AG,Butterworth D,Cole M, et al.Naturally occurring beta-lactamase inhibitors with antibacterial activity.J Antibiot (Tokyo). 1976;29:668-669
29. Bebrone C,Lassaux P,Vercheval L, et al.Current challenges in antimicrobial chemotherapy: a focus on beta-lactamase inhibition.Drugs. 2010;70:651-679
30. Drawz S,Bonomo R.Three decades of beta-lactamase inhibitors.Clin Microbiol Rev. 2010;23:160-201
31. Lodise T,Lomaestro B,Rodvold K,Danzinger L,Drusano G.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.Antimicrob Agents Chemother. 2004;48:4718-4724
32. Urban C,Go E,Mariano N,Rahal JJ.Interaction of sulbactam, clavulanic acid, and tazobactam with penicillin-binding proteins of imipenem-resistant and imipenem-susceptible Acinetobacter baumannii.FEMS Microbiol Lett. 1995;125:193-197
33. Poulikakos P,Tansarli G,Falagas M.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively-drug resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Euro J Clin Microbiol Infect Dis. 2014;33:1675-1685
34. Kuck N,Jacobus N,Petersen P,Weiss W,Testa R.Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.Antimicrob Agents Chemother. 1989;33:1964-1969
35. Totir MA,Cha J,Ishiwata A, et al.Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta lactamases: Raman crystallographic evidence.Biochemistry. 2008;47:4094-4101
36. Payne D,Cramp R,Winstanley D,Knowles D.Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.Antimicrob Agents Chemother. 1994;38:767-772
37. Sood S.Comparative evaluation of the in-vitro activity of six beta-lactam/beta-lactamase inhibitor combinations against Gram negative bacilli.J Clin Diagn Res. 2013;7:224-228
38. Bonfiglio G,Laksai Y,Franchino L,Amicosante G,Nicoletti G.Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey.J Antimicrob Chemother. 1998;42:697-702
39. Craig WA,Andes DR.In vivo activities of Ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum-lactamases, in the thighs of neutropenic mice.Antimicrob Agents Chemother. 2013;57:1577-1582
40. Wagenlehner F,Umeh O,Huntington J, et al.Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)/pyelonephritis in hospitalized adults: results from the phase 3 ASPECT-cUTI trial (abstract eP449).Paper presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Barcelona, Spain;.
41. Eckmann C,Hershberger E,Miller B, et al.Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalized adults: results from the phase 3 ASPECT-cIAI trial (abstract P0266-a).Paper presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Barcelona, Spain;.
42. Cubist Pharmaceuticals. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). http://clinicaltrials.gov/ct2/show/NCT02070757. NLM Identifier: NCT02070757. Accessed August 11, 2014.
43. Coleman K.Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors.Curr Opin Microbiol. 2011;14:550-555
44. Shales D.New beta-lactam/beta-lactamase inhibitor combinations in clinical development.Ann N Y Acad Sci. 2013;1277:105-114
45. Lahiri SD,Mangani S,Durand-Reville T, et al.Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases.Antimicrob Agents Chemother. 2013;57:2496-2505
46. Stachyra T,Péchereau MC,Bruneau JM, et al.Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.Antimicrob Agents Chemother. 2010;54:5132-5138
47. Boucher H,Talbot G,Benjamin D, et al.10x’20 Progress: development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America.Clin Infect Dis. 2013;56:1685-1694
48. Ehmann D,Jahic H,Ross P, et al.Kinetics of avibactam inhibition against class A, C and D beta-lactamases.J Biol Chem. 2013;288:27960-27971
49. Stachyra T,Levasseur P,Péchereau MC, et al.In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.Antimicrob Agents Chemother. 2009;64:326-329
50. Ehmann D,Jahic H,Ross PL, et al.Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor.Proc Natl Acad Sci U S A. 2012;109:11663-11668
51. AztraZeneca. Ceftazidime-avibactam for the treatment of infections due to ceftazidime resistant pathogens. http://clinicaltrials.gov/ct2/show/NCT01644643?term=avibactam&rank=6. Accessed January 2, 2014.
52. AztraZeneca. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. http://clinicaltrials.gov/ct2/show/NCT01808092?term=avibactam&rank=11. Accessed January 27, 2014.
53. Cerexa, Inc. Comparative study of coadministered ceftaroline foxamil and NXL 104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. http://clinicaltrials.gov/ct2/show/NCT01281462?term=avibactam&rank=5. Accessed January 2, 2014.
54. AstraZeneca. To investigate the safety and tolerability of aztreonam-avibactam (ATM-AVI). http://clinicaltrials.gov/ct2/show/NCT01689207?term=aztreonam+avibactam&rank=1. Accessed August 11, 2014.
55. Levasseur P,Girard AM,Claudon M, et al.In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.Antimicrob Agents Chemother. 2012;56:1606-1608
56. Crandon J,Shuck V,Banevicius M, et al.Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2012;56:6137-6146
57. Walkty A,DeCorby M,Lagace-Wiens PRS,Karlowsky J,Hoban D,Zhanel G.In vitro activity of ceftazidime combined with nxl104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals.Antimicrob Agents Chemother. 2011;55:2992-2994
58. Mushtaq S,Warner M,Livermore D.In vitro activity of ceftazidime1NXL104 against Pseudomonas aeruginosa and other non-fermenters.J Antimicrob Chemother. 2010;65:2376-2381
59. Lister P,Wolter D,Hanson N.Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Clin Microbiol Rev. 2009;22:582-610
60. Atkas Z,Kayacan C,Oncul O.In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae.Int J Antimicrob Agents. 2012;39:86-89
61. Endimiani A,Hujer K,Hujer A,Pulse M,Weiss W,Bonomo R.Evaluation of ceftazidime and NXL 104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.Antimicrob Agents Chemother. 2011;55:82-85
62. Dubreuil LJ,Mahieux S,Neut C,Miossec C,Pace J.Anti-anaerobic activity of a new beta-lactamase inhibitor NXL104 in combination with beta-lactams and metronidazole.Int J Antimicrob Agents. 2012;39:500-504
63. Lucasti C,Popescu I,Ramesh M,Lipka J,Sable C.Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole in the treatment of intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial.J Antimicrob Chemother. 2013;68:1183-1192
64. Vazquez JA,Gonzalez Patzan LD,Stricklin D, et al.Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.Curr Med Res Opin. 2012;28:1921-1931
65. AstraZeneca. Comparative study of NXL104/ceftazidime versus comparator in adults with complicated urinary tract infections. http://clinicaltrials.gov/ct2/show/NCT00690378?term=avibactam&rank=15. Accessed August 18, 2011.
66. Ceftazidime/avibactam trials. http://clinicaltrials.gov/ct2/show/NCT01726023?term=ceftazidime%2Favibactam&rank=4. Accessed February 10, 2014.
67. Biek D,Critchley IA,Riccobene TA,Thye DA.Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.J Antimicrob Chemother. 2010;65:iv9-iv16
68. Karlowsky J,Adam H,Decorby M,Lagace-Wiens P,Hoban D,Zhanel GG.In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Antimicrob Agents Chemother. 2011;55:2837-2846
69. Sader H,Flamm R,Jones R.Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from US medical centers in 2010-2011.Antimicrob Agents Chemother. 2013;57:1982-1988
70. Mushtaq S,Warner M,Williams G,Critchley I,Livermore D.Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.J Antimicrob Chemother. 2010;65:1428-1432
71. AztraZeneca. A study to investigate the effect of administration of ceftazidime-avibactam (CAZ-AVI) and ceftaroline fosamil-avibactam (CXL) on the intestinal flora of healthy volunteers. http://clinicaltrials.gov/ct2/show/NCT01789528. Accessed December 5, 2013.
72. AstraZeneca. To investigate the safety and tolerability of aztreonam-avibactam (ATM-AVI). http://clinicaltrials.gov/show/NCT01689207. Accessed January 2, 2014.
73. Livermore DM,Mushtaq S,Warner M, et al.Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae.Antimicrob Agents Chemother. 2011;55:390-394
74. Young K,Raghoobar S,Hairston N, et al.In vitro activity of the class A and class C beta-lactamase inhibitor MK-7655 [abstract F1-2139].Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting; Boston, MA;.
75. Livermore D,Warner M,Mushtaq S.Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.J Antimicrob Chemother. 2013;68:2286-2290
76. Hirsch E,Ledesma K,Chang KT,Schwartz M,Motyl M,Tam V.In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem resistant Gram-negative bacteria.Antimicrob Agents Chemother. 2012;56:3753-3757
77. Young K,Hackel M,Lascols C, et al.Response to imipenem plus MK-7655, a novel beta-lactamase inhibitor, in a surveillance study population of P. aeruginosa from SMART 2009.Paper presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting; San Francisco, CA;.
78. Wayne, PA: Clinical Laboratory Standards Institute; 2007:
79. Wayne, PA: Clinical Laboratory Standards Institute; 2014:
80. Merck Sharp & Dohme Corp. Study of the safety, tolerability, and efficacy of MK-7655 + imipenem/cilastatin alone for the treatment of complicated urinary tract infection (cUTI). http://clinicaltrials.gov/ct2/show/NCT01505634?term=MK-7655&rank=2. Accessed January 22, 2014.
81. Merck Sharp & Dohme Corp. Study of the safety, tolerability, and efficacy of MK-7655 + imipenem/cilastatin versus imipenem/cilastatin alone to treat complicated intra-abdominal infection [cIAI]. http://clinicaltrials.gov/ct2/show/NCT01506271?term=MK-7655&rank=3. Accessed January 15, 2014.
82. Merck Sharp & Dohme Corp. Merck’s investigational beta-lactamase inhibitor relebactam (MK-7655) granted qualified infectious disease product (QIDP) and fast track designations by FDA. http://www.mercknewsroom.com/news-release/cor-porate-news/mercks-investigational-beta-lactamase-inhibitor-relebactam-mk-7655-grant. Accessed October 9, 2014.
83. Rempex Pharmaceuticals. Rempex Pharmaceuticals to present data at ICAAC on Carbavance, a new agent designed to treat multi-drug resistant (MDR) Gram-negative bacteria, September2012. http://www.rempexpharma.com/news/9-7-12. Accessed January 18, 2014.
84. Chen HY,Livermore DM.In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.J Antimicrob Chemother. 1994;33:949-958
85. Livermore D,Mushtaq S.Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.J Antimicrob Chemother. 2013;68:1825-1831
86. Goldstein E,Citron D,Tyrrell K,Merriam C.In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria.Antimicrob Agents Chemother. 2013;57:2620-2630
87. Brismar B,Akerlund JE,Sjostedt S, et al.Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish study group.Scand J Infect Dis. 1996;28:507-512
88. Efficacy, safety, tolerability of carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults. http://clinicaltrials.gov/ct2/show/NCT02168946?term=RPX7009&rank=6. Accessed October 21, 2014.
89. Endimiani A,Luzzaro F,Perilli M.Bacteremia due to Klebsiella pneumonia isolates producing the TEM-52 Extended-spectrum beta-lactamase: Treatment outcome of patients receiving imipenem or ciprofloxacin.Clin Infect Dis. 2004;38:243-251
90. Paterson D,Wen-Chien K,Gottberg A, et al.Antibiotic therapy for Klebsiella pneumonia bacteremia: implications of the production of extended-spectrum beta-lactamases.Clin Infect Dis. 2003;39:31-37
91. Pitout JD,Laupland KB.Extended spectrum beta-lactamase producing Enterobacteriaceae: an emerging public-health concern.Lancet Infect Dis. 2008;8:159-166
92. Mentec H,Vallois JM,Bure A, et al.Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumonia or its susceptible variant.Antimicrob Agents Chemother. 1992;36:1883-1889
93. Rice LB,Carias LL,Shales DM.In vivo efficacies of beta-lactam beta-lactamase inhibitor combinations in Klebsiella pneumonia and in vivo response to beta-lactam therapy.J Infect Dis. 1996;173:151-158
94. Perez F,Bonomo R.Can we really use beta-lactam/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria?.Clin Infect Dis. 2012;54:175-177
95. Thauvin-Eliopoulous C,Tripodi MF,Moellering JR,Eliopoulos GM.Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumonia.Antimicrob Agents Chemother. 1994;41:1053-1057
96. Thompson K,Smith Moland E.Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.Antimicrob Agents Chemother. 2001;45:3548-3554
97. Lopez-Cerero L,Picon E,Morillo C, et al.Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin/clavulanate and piperacillin/tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-nonproducing Escherichia coli isolates.Clin Microbiol Infect. 2010;16:132-136
98. Docobo-Perez F,Lopez-Cereo L,Lopez-Rojas R, et al.Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in an experimental murine sepsis model.Antimicrob Agents Chemother. 2013;57:2109-2113
99. Rahal JJ,Urban C,Horn D, et al.Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.JAMA. 1998;280:1233-1237
100. McLaughlin M,Advincula MR,Malcynski M, et al.Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae.Antimicrob Agents Chemother. 2013;57:5131-5133
101. Siedner M,Galar A,Guzman-Suarez BB, et al.Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.Clin Infect Dis. 2014;58:1554-1563
102. Park S,Choi S,Lee D.The efficacy of non-carbapenem antibiotics for the treatment of community-onset pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli.J Antimicrob Chemother. 2014;69:2848-2856
103. Vardakas K,Tansarli G,Rafailidis P,Falagas M.Carbapenems versus alternative antibiotics for the treatment of bacteremia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis.J Antimicrob Chemother. 2012;67:2793-2803
104. Rodriguez-Bano J,Navarro M,Retamar P, et al.Beta lactam/beta lactam inhibitor combinations for the treatment of bacteremia due to Extended-spectrum Beta-lactamase producing Escherichia coli: a post hoc analysis of prospective cohorts.Clin Infect Dis. 2012;54:167-174
105. Gavin P,Suseno M,Peterson L.Clinical correlation of CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.Antimicrob Agents Chemother. 2006;50:2244-2247
106. Bhavnani S,Ambrose P,Craig W.Outcomes evaluation of patients with ESBL and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.Diagn Microbiol Infect Dis. 2006;54:231-236
107. Craig W.The inoculum effect: fact or artifact?.Diagn Microbiol Infect Dis. 2004;50:229-230
108. Dudley M,Ambrose P,Bhavnani SM, et al.Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Entero-bacteriaceae and Pseudomonas aeruginosa: I. cephalosporins and aztreonam.Clin Infect Dis. 2013;56:1301-1309
109. Retamar P,Lopez-Cerero L,Muniain M, et al.Impact of the MIC of piperacillin/tazobactam on the outcome of patients with bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli.Antimicrob Agents Chemother. 2013;57:3402-3404
110. Peterson L.Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin/tazobactam.Clin Microbiol Infect. 2008;14:181-184
111. Johnson A,Woodford N.Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance.J Med Microbiol. 2013;62:599-613
112. Ahammad Z,Sreekrishnan T,Hands C,Knapp C,Graham D.Increased waterborne blaNDM-1 resistance gene abundances associated with seasonal human pilgrimages to the upper Ganges river.Environ Sci Technol. 2013;48:3014-3020